An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
REACH-AD
REal-world Utilization and Treatment Target ACHievement With Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis in China
1 other identifier
observational
1,000
1 country
38
Brief Summary
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Upadacitinib is an approved drug for treating AD. Approximately 1000 adolescents and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in up to 40 sites in China. Participants will receive oral upadacitinib tablets as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed up for approximately 12 months. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2024
38 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 15, 2024
CompletedFirst Posted
Study publicly available on registry
May 20, 2024
CompletedStudy Start
First participant enrolled
June 7, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
CompletedMay 13, 2026
May 1, 2026
2 years
May 15, 2024
May 11, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Number of participants with a dose change
Dose change includes: Changed dose, dose escalation or dose tapering.
12 Months
Number of participants with Upadacitinib drug compliance
The participants missed medication, regardless of reason, or incompliance with the prescription as per medical advice are to be recorded in the eDiary, choosing the reason: "Forgot, Self-reduction of medication, interruption because of AE, interruption not due to safety/tolerability, for other reasons". If no eDiary entries are found within 30 days before the visit, the participant will need to complete the following question in ePRO: timely Upadacitinib intake per medical advice in past 30 days (yes/no); if "no", days-off-drug, intentionally or accidentally, and if "intentionally", reason for incompliance with medical prescription.
12 Months
Number of participants with interruption or permanent discontinuation
Interruption: Upadacitinib is temporarily interrupted due to atopic dermatitis disease condition, economic, tolerance, AE, or personal reasons, and the investigator considers there is still possibility of Upadacitinib re-initiating within the patient's study follow-up period. Discontinuation: Upadacitinib is permanently discontinued for safety or any other reasons, and the investigator considers Upadacitinib will not be used again, at least within the participant's study follow-up period.
12 Months
Study Arms (1)
Upadacitinib
Participants will receive upadacitinib as prescribed by their physician according to local label.
Eligibility Criteria
Adolescent and adult Chinese participants with atopic dermatitis (AD) who are prescribed Upadacitinib by their physician according to their local label.
You may qualify if:
- Adolescents (body weight \>= 40 kg at the Baseline Visit for patients between \>= 12 and \< 18 years of age) and adults at the time of enrollment.
- Clinical diagnosis of moderate to severe atopic dermatitis at the time of enrollment.
- UPA treatment is indicated for AD and prescribed as per Chinese label / SmPC.
- The decision to prescribe UPA is made prior to and independent of study participation.
- The participant should not be treated with UPA prior to this study.
- Participants who are willing and able to participate in the collection of patient-reported data, including ePROs and eDiary via apps.
- The participant (legal representative for adolescents) voluntarily signed an informed consent before any study-related activities are conducted.
You may not qualify if:
- The participant is currently participating in interventional research (not including noninterventional study, observational study, or registry participation).
- Any circumstances that the investigator believes may limit the patient's participation and compliance with study procedures.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AbbVielead
Study Sites (38)
Beijing Anzhen Hospital /ID# 273443
Beijing, Beijing Municipality, 100029, China
China-Japan Friendship Hospital /ID# 274778
Beijing, Beijing Municipality, 100029, China
Peking University First Hospital /ID# 274865
Beijing, Beijing Municipality, 100034, China
Peking Unversity Third hospital /ID# 274864
Beijing, Beijing Municipality, 100191, China
Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 264193
Beijing, Beijing Municipality, 100730, China
The First Affiliated Hospital Of Fujian Medical University /ID# 268210
Fuzhou, Fujian, 350005, China
Changgeng Hospital /ID# 268209
Xiamen, Fujian, 361022, China
Guangzhou Dermatology Hospital /ID# 271684
Guangzhou, Guangdong, 510095, China
The Fifth Affiliated Hospital Of Sun Yat-Sen University /ID# 268618
Zhuhai, Guangdong, 519000, China
Hainan Fifth People's Hospital /ID# 269747
Hainan, Hainan, 200000, China
Hebei Engineering University Affiliated Hospital /ID# 268660
Handan, Hebei, 200000, China
The Second Affiliated Hospital Of Harbin Medical University /ID# 270872
Harbin, Heilongjiang, 150001, China
People's Hospital of Henan Province /ID# 269744
Zhengzhou, Henan, 450003, China
Wuhan Integrated TCM & Western Medicine Hospital（Wuhan No.1 Hospital) /ID# 272374
Wuhan, Hubei, 430022, China
Tongji Hospital /ID# 269745
Wuhan, Hubei, 430030, China
Xiangya Hospital Central South University /ID# 272373
Changsha, Hunan, 410008, China
Nanjing Drum Tower Hospital /ID# 268616
Nanjing, Jiangsu, 210008, China
Affiliated Hospital Of Nantong University /ID# 269743
Nantong, Jiangsu, 226001, China
The First Affiliated Hospital of Soochow University /ID# 269742
Suzhou, Jiangsu, 215006, China
The Affiliated Hospital of Xuzhou Medical College /ID# 268208
Xuzhou, Jiangsu, 221006, China
Dalian Dermatosis Hospital /ID# 272495
Dalian, Liaoning, 116041, China
The People's Hospital of Liaoning Province /ID# 268206
Shenyang, Liaoning, 110016, China
Shandong Provincial Hospital /ID# 268661
Jinan, Shandong, 250001, China
Jining Medical University - Affiliated Hospital /ID# 270873
Jining, Shandong, 272029, China
Weifang People'S Hospital /ID# 268659
Weifang, Shandong, 261041, China
Ruijin Hospital /ID# 268658
Shanghai, Shanghai Municipality, 200025, China
Huashan Hospital Of Fudan University /ID# 270277
Shanghai, Shanghai Municipality, 200040, China
Shanghai Sixth People'S Hospital /ID# 268617
Shanghai, Shanghai Municipality, 200233, China
Shanghai Skin Disease Hospital /ID# 268657
Shanghai, Shanghai Municipality, 200443, China
West China Hospital of Sichuan University /ID# 268313
Chengdu, Sichuan, 610041, China
Sichuan Provincial People's Hospital /ID# 268314
Chengdu, Sichuan, 610072, China
The Affiliated Hospital Of Southwest Medical University /ID# 268207
Luzhou, Sichuan, 646600, China
People's Hospital of Xinjiang Uygur Autonomous Region /ID# 269746
Ürümqi, Xinjiang, 830001, China
The First Affiliated Hospital of Kunming Medical College /ID# 273451
Kunming, Yunnan, 650032, China
Zhejiang Provincial Hospital of Chinese Medicine /ID# 268613
Hangzhou, Zhejiang, 310006, China
Ningbo No.6 hospital /ID# 268315
Ningbo, Zhejiang, 315040, China
Taizhou Central Hospital /ID# 268211
Taizhou, Zhejiang, 318000, China
Zhuji People'S Hospital /ID# 268614
Zhuji, Zhejiang, 315000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
ABBVIE INC.
AbbVie
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 15, 2024
First Posted
May 20, 2024
Study Start
June 7, 2024
Primary Completion
June 1, 2026
Study Completion
June 1, 2026
Last Updated
May 13, 2026
Record last verified: 2026-05